1 Start 2 Complete Please select your profession: * Physician Nurse Nurse Practitioner Pharmacist Dentist Physician Assistant Other... Please select your profession: Other... How would you best describe your practice setting? * Private physician office/practice Private NP office/practice Nurse Managed clinic Retail-based clinic Urgent care clinic Hospital inpatient unit Hospital outpatient clinic (not an ED) Long-term care facility Average years in practice: * <5 5-10 11-15 6-20 21-25 >25 Average number of patients seen per week with disease targeted in the education: * <5 5-10 11-15 16-20 21-25 >25 In the ruxolitinib cream trials, total-body response consistently lagged facial response. For example, among patients treated from day 1, 50.3% reached F-VASI75 at week 52, while 36.4% reached T-VASI50. Which explanation best accounts for this pattern? * Ruxolitinib penetrates facial skin poorly, so facial response should be the slower of the two Total-body endpoints were not measured until after week 52 Repigmentation depends on melanocyte repopulation from surviving reservoirs, which differ by anatomic site, so facial and total-body endpoints move at different speeds Slower total-body response shows that topical therapy fails on the body and that systemic therapy is required for all non-facial lesions In the TRuE-V long-term extension, patients who reached F-VASI90 at week 52 were randomized to either continue ruxolitinib cream or switch to vehicle. Which statement best summarizes the week-104 results and their interpretation? * Maintenance rates were similar in both arms, so cream can be stopped once F-VASI90 is reached About 62% maintained F-VASI90 with continued treatment versus about 21% after withdrawal, consistent with persistence of tissue-resident memory T cells (TRM) The withdrawal arm maintained response better, suggesting tachyphylaxis with continued use Nearly all patients in the withdrawal arm lost response within weeks, so withdrawal should never be considered A patient with extensive non-segmental vitiligo is considering an oral JAK inhibitor. Which approach to safety counseling and monitoring is most consistent with the evidence and labeling? * Because no new safety signals emerged in the vitiligo programs, baseline laboratory testing and tuberculosis screening can be omitted Obtain baseline and periodic complete blood count, lipid panel, and hepatic panel; screen for tuberculosis; assess cardiovascular and malignancy risk; and discuss the boxed warning in the context of a non-life-threatening disease Quote the event rates behind the boxed warning as the patient's expected individual risk Because raised creatine kinase was among the most common events, monitoring should focus on muscle enzymes rather than blood counts and lipids A 27-year-old woman has segmental vitiligo on her left forehead and temple. The area has not changed in 3 years: she has had no new lesions, no lesion enlargement, and no Koebner phenomenon. Several hairs within the patch are white. She used tacrolimus 0.1% ointment and targeted phototherapy for 12 months with minimal repigmentation, and she is asking about further options. Which next step best fits the evidence? * Start an oral JAK inhibitor to halt the autoimmune attack Begin full-body NB-UVB two to three times weekly for at least 12 months Refer for evaluation for melanocyte transfer, such as cellular grafting Observe without treatment, since stable disease will repigment on its own Leave this field blank
